HIRU CORPORATION (Other OTC: HIRU.PK) is very pleased to announce that main subsidiary Jiangxi Shuangshi Animal Health Products (AHP) has been awarded the 2009 Trustworthy AA Grade Enterprise Certificate.

This great honor, presented by the Nanchang City Industry and Commerce Administration, confirms Shuangshi AHP's status as a rising star in the field of animal health products.

The Nanchang City Industry and Commerce Administration is a government body that oversees the planning, development, implementation and inspection of all industrial and technological enterprises in the province of Jiangxi. Based in Nanchang's Xiaolan Industrial Park, Shuangshi AHP provides the Chinese agricultural market with veterinary and animal nutrition solutions which include large volume injections, liquid disinfectants and feed additives.

Shuangshi AHP expects that this Certificate, along with the awarded 2009 Annual Growth Honor Award will help the company's efforts in marketing and branding its products on the Chinese market for animal health products. This recognition on the local level should enhance the company name on the national market for animal health products and raise the potential for landing new contracts and customers.

Hiru Corporation's subsidiary Shuangshi Animal Health Products (AHP) Co. focuses on delivering veterinary and animal nutrition solutions for the Chinese agricultural market. The company operates in the Nanchang (Xiaolan) Economic Development Zone, and produces products that foster livestock health such as injections, volume injections, large volume injections, oral liquids, liquid disinfectants, feed additives, loose powders and feed premixes.

*********************************************************

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

*********************************************************

SunOpta Inc. (Nasdaq:STKL) has signed definitive agreements to acquire 100% of the outstanding shares of Dahlgren & Company, Inc. (”Dahlgren”), on a debt free basis, for cash consideration of $44 million, subject to normal post closing adjustments, plus an earn-out based on pre-determined targets over the next two years.

The transaction is expected to be completed by the close of business today.

*********************************************************

Athersys, Inc. (Nasdaq:ATHX) reported that the U.S. Food and Drug Administration (FDA) has authorized commencement of a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem(r), ATHX’s allogeneic investigational cell therapy product, for the potential treatment of ulcerative colitis.

This Phase II clinical trial is expected to begin enrolling patients before the end of 2010 and is part of a collaboration between ATHX and Pfizer that the companies formed in December 2009 to develop MultiStem for the treatment of inflammatory bowel disease (IBD).

*********************************************************

Celcom, the largest 3G mobile operator in Malaysia, reported that it has selected Motricity (Nasdaq:MOTR) to provide the technology platform that will deliver personalized, relevant mobile experiences to Celcom’s 11million feature and 3G Smartphone subscribers.

MOTR’s mCore Platform will offer Celcom subscribers a personalized mobile Internet browsing experience with the content and information they want on their mobile phones.

*********************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Hiru Corporation (HIRU.PK)

Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB).